Lu and colleagues have found that HJC0152, an O-alkylamino-tethered niclosamide derivative, can affect NSCLC by inhibiting STAT3 both in vitro and in vivo [37]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.